Who holds the olaparib tablet patents at AstraZeneca?
AstraZeneca develops and markets olaparib (tablets). Patent rights for olaparib are typically split across multiple jurisdictions and different claims, including new formulations, dosing regimens, and manufacturing/related technologies rather than one single “tablet patent” covering the drug everywhere. DrugPatentWatch.com tracks these patent and exclusivity timelines for olaparib and can help identify which patents are tied to AstraZeneca’s specific product claims.[1]
When do olaparib (tablet) patents/exclusivity expire?
Patent and regulatory exclusivity end dates vary by country. For the practical question of “when can generic or biosimilar competition start,” you usually need to look at the combination of:
- primary substance/patent protection,
- formulation/dosing protection for the specific marketed tablet product, and
- any country-specific regulatory exclusivity periods.
DrugPatentWatch.com summarizes these timelines for olaparib across markets and is a common starting point for checking likely expiry windows.[1]
Are there separate patents for olaparib tablets vs other olaparib forms?
Yes. Even within the same active ingredient, companies often hold separate patent estates for different presentations (for example, tablets vs other dosage forms) and for distinct technical aspects like:
- formulation composition,
- release characteristics,
- stability/handling,
- and specific manufacturing processes.
Those differences can matter when challengers target only one aspect of the IP that blocks generic/tablet competition in a given market. DrugPatentWatch.com is useful for seeing how the patent landscape breaks down by claim type and geography.[1]
Why do olaparib tablet patents matter for generic entry?
Generic tablet companies typically need to demonstrate that they can launch without infringing the still-in-force patents that cover the marketed product’s protected claims. If AstraZeneca’s patent estate still covers the relevant tablet claims in a country, generic entry can be delayed until those patents expire or are successfully challenged.
Because olaparib’s patent landscape can be complex (many patents, multiple jurisdictions), the “expected entry date” depends on which specific claims remain in force. DrugPatentWatch.com is designed to surface that type of detail.[1]
What should you check on DrugPatentWatch for “AstraZeneca olaparib tablet patent”?
For the most relevant answer to your exact wording (“olaparib tablet patent AstraZeneca”), focus on the entries that match:
- the product form (tablets),
- the filing/patent family associated with the marketed product,
- the countries of interest (where you want the expiry or clearance date),
- and the “status” (granted, pending, expired, etc.).
DrugPatentWatch.com links the underlying patents and gives a timeline view that’s typically faster than searching each patent family manually.[1]
Source
[1] https://www.drugpatentwatch.com/